On April 10th, 2013, our first “all-online” Journal Club was moderated by Dr. med. Richard Cathomas and joined by PD Dr. med. Frank Stenner and Dr. med. Philippe von Burg. The paper discussed was 2-weekly vs. 3-weekly docetaxel to treat castration-resistant prostate cancer: a randomised phase 3 trial by Kellokumpu-Lehtinen et al.; Lancet Oncology 2013;14:117-124 (abstract).
After a short introduction to the paper by Richard Cathomas, the participant discussed the value and the limitations of the finding that a 2-weekly administration of docetaxel leads to comparable results to a 3-weekly scheme, if a change of therapy will be implemented in their clinical work and if so, for which patients.
Please post questions or comments above (leave a reply) and we will refer them to the discussants.